Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Proarrhythmias due to drug‐induced QT prolongation are the second most common cause for drug withdrawal and have caused increasing concern. Two new International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines were recently endorsed in which nonclinical (S7B) and clinical (E14) methodologies are discussed and guidance is given to the industry. This commentary describes the key components of the E14 document, the impact of nonclinical testing on the clinical program, the thorough QT study, and the impact of its result on late‐stage development. The studies described in S7B and E14 will contribute to a better understanding of the link between nonclinical assays and QT prolongation in humans. Differences in interpretation among individual regulators in the major regions with respect to measures proposed in the E14 guideline might impact regional regulatory decisions. These differences include the value of nonclinical assays for the subsequent clinical testing and how predictive a negative thorough QT study result is for proarrhythmic risk in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug induced QT prolongation and torsades de pointes
Yap, Y. G., & Camm, A. J. (2003) · Heart · doi:10.1136/heart.89.11.1363 · Cited by 958
Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences
Honig, P. K. (1993) · JAMA · doi:10.1001/jama.1993.03500120051025 · Cited by 664 · cited 2×
“This concept remains to be proven, but evidence supports that for all drugs that have been associated with TdP, it has been possible to show a QT effect in carefully designed studies in healthy volunteers.(15-19) Certain drugs, such as dopamine agonists, neuroleptics, and chemotherapeutics, cannot be readily tested in…”
BackgroundMalik, M., Färbom, P., Batchvarov, V, Hnatkova, K., & Camm, A. J. (2002) · Heart · doi:10.1136/heart.87.3.220 · Cited by 436
Cisapride and Fatal Arrhythmia
Wysowski, D. K., & Bacsanyi, J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607253350416 · Cited by 331
Problems of Heart Rate Correction in Assessment of Drug‐Induced QT Interval Prolongation
MALIK, M. (2001) · Journal of Cardiovascular Electrophysiology · doi:10.1046/j.1540-8167.2001.00411.x · Cited by 276
Evaluation of Drug-Induced QT Interval Prolongation: Implications for Drug Approval and Labelling
Malik, M., & Camm, A. J. (2001) · Drug Safety · doi:10.2165/00002018-200124050-00001 · Cited by 273
The significance of QT interval in drug development
Shah, R. R. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01627.x · Cited by 231
Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes
DARPO, B. (2001) · European Heart Journal Supplements · doi:10.1016/s1520-765x(01)90009-4 · Cited by 205
Self-citationDémolis, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.111482 · Cited by 155
Effects of three fluoroquinolones on QT interval in healthy adults after single doses
Noel, G. J., Natarajan, J., Chien, S., Hunt, T. L., Goodman, D. B., & Abels, R. I. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00009-2 · Cited by 153
The influence of cisapride and clarithromycin on QT intervals in healthy volunteers
van Haarst, A. D., Klooster, G. A. E. V. '., van Gerven, J., Schoemaker, R. C., van Oene, J. C., Burggraaf, J., Coene, M. C., & Cohen, A. F. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90137-0 · Cited by 147
Pratt, C. M., Ruberg, S. J., Morganroth, J., McNutt, B. E., Woodward, J. K., Harris, S. I., Ruskin, J. N., & Moyé, L. A. (1996) · American Heart Journal · doi:10.1016/s0002-8703(96)90525-6 · Cited by 143
HOULTZ, B., DARPÖ, B., EDVARDSSON, N., BLOMSTRÖM, P., BRACHMANN, J., CRIJNS, H. J. G. M., JENSEN, S. M., SVERNHAGE, E., VALLIN, H., & SWEDBERG, K. (1998) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.1998.tb00150.x · Cited by 117
Sarapa, N., Morganroth, J., Couderc, J., Francom, S. F., Darpö, B., Fleishaker, J. C., McEnroe, J. D., Chen, W. T., Zaręba, W., & Moss, A. J. (2004) · Annals of Noninvasive Electrocardiology · doi:10.1111/j.1542-474x.2004.91546.x · Cited by 97
Influence of age, the autonomic nervous system and anxiety on QT-interval variability
Piccirillo, G., Cacciafesta, M., Lionetti, M., Nocco, M., Giuseppe, V. D., Moisè, A., Naso, C., & Marigliano, V. (2001) · Clinical Science · doi:10.1042/cs1010429 · Cited by 92
The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada
Walker, A. M., Szneke, P., Weatherby, L. B., DICKER, L. W., Lanza, L. L., Loughlin, J. E., Yee, C. L., & Dreyer, N. A. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00241-7 · Cited by 88
Man Versus Machine: Is There an Optimal Method for QT Measurements in Thorough QT Studies?
Darpö, B., Agin, M. A., Kazierad, D. J., Layton, G. R., Muirhead, G. J., Gray, P., & Jorkasky, D. K. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006286900 · Cited by 86
Modulation of QT Interval During Autonomic Nervous System Blockade in Humans
Diedrich, A., Jordan, J., Shannon, J. R., Robertson, D., & Biaggioni, I. (2002) · Circulation · doi:10.1161/01.cir.0000035241.76918.6c · Cited by 78
Shah, R. R. (2002) · Fundamental and Clinical Pharmacology · doi:10.1046/j.1472-8206.2002.00083.x · Cited by 76
Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride
Kivistö, K. T., Lilja, J. J., Backman, J. T., & Neuvonen, P. J. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70007-x · Cited by 74
Barbey, J. T., Lazzara, R., & Zipes, D. P. (2002) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840200700202 · Cited by 71
Arrhythmogenic mechanisms of non‐sedating antihistamines
Yap, Y. G., & Camm, A. J. (1999) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.1999.0290s3174.x · Cited by 70
Clinical assessment of drug-induced QT prolongation in association with heart rate changes
Extramiana, F., Maison‐Blanche, P., CABANIS, M., Ortemann‐Renon, C., Beaufils, P., & Leenhardt, A. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.10.016 · Cited by 68
QTc Interval (Cardiac Repolarization): Lengthening After Meals
Nagy, D., DeMeersman, R. E., Gallagher, D., Pietrobelli, A., Zion, A. S., Daly, D., & Heymsfield, S. B. (1997) · Obesity Research · doi:10.1002/j.1550-8528.1997.tb00573.x · Cited by 57
Terfenadine-associated ventricular arrhythmias and QTc interval prolongation
Hanrahan, J. P., Choo, P. W., Carlson, W., Greineder, D. K., Faich, G. A., & Platt, R. G. (1995) · Annals of Epidemiology · doi:10.1016/1047-2797(94)00039-v · Cited by 55
Drug‐induced prolongation of the QT interval: why the regulatory concern?
Shah, R. R. (2002) · Fundamental and Clinical Pharmacology · doi:10.1046/j.1472-8206.2002.00082.x · Cited by 46
Azie, N. E., Adams, G., Darpö, B., Francom, S. F., Polasek, E. C., Wisser, J. M., & Fleishaker, J. C. (2004) · Annals of Noninvasive Electrocardiology · doi:10.1111/j.1542-474x.2004.92542.x · Cited by 43
Cardiac safety of noncardiac drugs : practical guidelines for clinical research and drug development
Morganroth, J., & Gussak, I. B. (2005) · DIAL (Catholic University of Leuven) · doi:10.1007/978-1-59259-884-7 · Cited by 29
Computer‐Based Analysis of Dynamic QT Changes: Toward High Precision and Individual Rate Correction
Dota, C., Skallefell, B., Edvardsson, N. G., & Fager, G. (2002) · Annals of Noninvasive Electrocardiology · doi:10.1111/j.1542-474x.2002.tb00177.x · Cited by 25
Influence of autonomic tone on QT interval duration.
Cuomo, S., Caprio, L. D., Palma, A. D., Lirato, C., Lombardi, L., Rosa, M. L. D., Vetrano, A., & Rengo, F. (1997) · PubMed · Cited by 20
Moxifloxacin Does Increase the Corrected QT Interval
White, C. M., Grant, E. M., & Quintiliani, R. (2001) · Clinical Infectious Diseases · doi:10.1086/323015 · Cited by 20
Cited by
Which QT Correction Formulae to Use for QT Monitoring?
Vandenberk, B., Vandael, E., Robyns, T., Vandenberghe, J., Garweg, C., Foulon, V., Ector, J., & Willems, R. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003264 · Cited by 404
Biederman, J., Boellner, S. W., Childress, A., Lopez, F. A., Krishnan, S., & Zhang, Y. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.015 · Cited by 360
Mirams, G. R., Cui, Y., Sher, A., Fink, M., Cooper, J., Heath, B. M., McMahon, N. C., Gavaghan, D. J., & Noble, D. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr044 · Cited by 326
Johannesen, L., Vicente, J., Mason, J. W., Sanabria, C., Waite-Labott, K., Hong, M., Guo, P., Lin, J., Sørensen, J. S., Galeotti, L., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.155 · Cited by 254
Chatterjee, D. J., Khutoryansky, N., Zdravkovic, M., Sprenger, C. R., & Litwin, J. S. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009339189 · Cited by 54
Metadata
- Authors
- Darpo, B., Nebout, T., & Sager, P. T.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2006-05
- Volume
- 46
- Issue
- 5
- Pages
- 498-507
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2038481443
- Cited by
- 319
- References
- 31
- FWCI
- 15.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.